Korea Joongang Daily
Korea JoongAng Daily

Daewoong Pharmaceutical's Nabota approved in Saudi Arabia and Ukraine

Daewoong Pharmaceutical's Nabota botulinum toxin won use approval from Saudi Arabia and Ukraine, the Korean company said Wednesday.

2022-05-18

Supreme Court dismisses appeal to suspend sales of Hugel's Botox

The Supreme Court dismissed an appeal filed by the Seoul Regional Office of Food and Drug Safety in an ongoing legal row over the suspension of the sale of Hugel's botulinum toxin products, Hugel said Wednesday.

2022-04-06

Hugel can sell its botulinum toxin product in U.K.

Hugel's Letybo botulinum toxin product was approved for sale in Britain, the company said Thursday.

2022-03-24

Hugel’s Letybo wins marketing approval from Austria

Letybo, Hugel’s botulinum toxin product, won marketing approval from health regulators in Austria, the company said Tuesday.

2022-02-22

Hugel wants to send its botulinum toxin around the world

Hugel’s main focus for 2022 is to go global, with the goal of claiming 10 percent of the world market share for botulinum toxin in five years.

2022-02-11

Hugel’s botulinum toxin product wins marketing approval in France

Letybo, Hugel’s botulinum toxin product, won marketing approval from health regulators in France, the company said Thursday.

2022-02-03

Gov't pulls license of six botulinum products

The Ministry of Food and Drug Safety will revoke the license of six botulinum toxin products manufactured by Hugel and Pharma Research Bio for violating certification and shipping regulations.

2021-12-03

Hugel celebrates 20 years with vow to go even more global

Hugel, Korea's largest botulinum toxin maker, wants 80 percent of its sales to come from overseas by 2025.

2021-11-22

Huons BioPharma signs big Hutox deal with Germany's Haemato Pharm

Huons BioPharma signed a deal potentially worth 97.2 billion won ($83.4 million) with Berlin, Germany’s Haemato Pharm to supply its Hutox botulinum toxin for sale in the European market.

2021-10-26

Nabota Phase 3 trials in China achieve meaningful results

Daewoong Pharmaceutical said Wednesday its Nabota botulinum toxin demonstrated statistically meaningful results in Phase 3 trials in China, signaling an imminent entry to the market, the second largest botulinum toxin market in the world.

2021-07-28